Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3a4 by activating p53

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 190-198

  Goldstein, Ido ^a   Rivlin, Noa ^a   Shoshana, Oryam ^a   Ezra, Osnat ^a   Madar, Shalom ^a   Goldfinger, Naomi ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AROMATASE; CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 19A2; CYTOCHROME P450 24A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A43; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 4F11; CYTOCHROME P450 4F12; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3; DOXORUBICIN; ETOPOSIDE; NUTLIN 3; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL ISOLATION; CELL STRAIN; CELL STRAIN HEPG2; CELL STRAIN HUH6; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; XENOBIOTIC METABOLISM;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CYTOCHROME P-450 CYP3A; DNA; HUMANS; LIPID METABOLISM; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872160824     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs318     Document Type: Article

References (36)

1. Nebert, D.W. et al. (2002) Clinical importance of the cytochromes P450. Lancet, 360, 1155-1162.
2. Nelson, D.R. et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1-18.
3. Harmsen, S. et al. (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev., 33, 369-380.
4. Zhou, S.F. (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 9, 310-322.
5. Desai, P.B. et al. (2002) Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos., 30, 608-612.
6. Dowsett, M. et al.; ATAC Trialists' Group. (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a subprotocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br. J. Cancer, 85, 317-324.
7. Plant, N. (2007) The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim. Biophys. Acta, 1770, 478-488.
8. Hardwick, J.P. (2008) Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol., 75, 2263-2275.
9. Kalsotra, A. et al. (2006) Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol. Ther., 112, 589-611.
10. Hsu, M.H. et al. (2011) Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. J. Pharmacol. Exp. Ther., 337, 125-136.
11. Goldstein, I. et al. (2011) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther., 18, 2-11.
12. Vousden, K.H. et al. (2009) Blinded by the Light: The Growing Complexity of p53. Cell, 137, 413-431.
13. Goldstein, I. et al. (2012) Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol. Metab., 23, 567-575.
14. Maddocks, O.D. et al. (2011) Metabolic regulation by p53. J. Mol. Med., 89, 237-245.
15. Imamura, K. et al. (2001) Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun., 287, 562-567.
16. Jones, R.G. et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell, 18, 283-293.
17. Hardie, D.G. (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev., 25, 1895-1908.
18. Ide, T. et al. (2009) GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol. Cell, 36, 379-392.
19. Kim, D.H. et al. (2011) Tumor suppressor p53 regulates bile acid homeostasis via small heterodimer partner. Proc. Natl. Acad. Sci. U.S.A., 108, 12266-12270.
20. Meivar-Levy, I. et al. (2007) Pancreatic and duodenal homeobox gene 1 induces hepatic dedifferentiation by suppressing the expression of CCAAT/ enhancer-binding protein beta. Hepatology, 46, 898-905.
21. Cali, J.J. et al. (2006) Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol., 2, 629-645.
22. Boehme, K. et al. (2010) Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro. Toxicol. Lett., 198, 272-281.
23. Javitt, N.B. (1990) Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J., 4, 161-168.
24. Vassilev, L.T. et al. (2004) In vivo activation of the p53 pathway by smallmolecule antagonists of MDM2. Science, 303, 844-848.
25. Goldstein, I. et al. (2012) p53, a novel regulator of lipid metabolism pathways. J. Hepatol., 56, 656-662.
26. Menendez, D. et al. (2009) The expanding universe of p53 targets. Nat. Rev. Cancer, 9, 724-737.
27. Hoh, J. et al. (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. U.S.A., 99, 8467-8472.
28. Assaily, W. et al. (2011) ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol. Cell, 44, 491-501.
29. Tishler, R.B. et al. (1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res., 53(10 SUPPL), 2212-2216.
30. Relling, M.V. et al. (1998) Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia, 12, 346-352.
31. Barpe, D.R. et al. (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur. J. Pharm. Sci., 41, 458-463.
32. Palm, C. et al. (2001) Quantification of doxorubicin in plasma-a comparative study of capillary and venous blood sampling. Anticancer. Drugs, 12, 859-864.
33. Himmelstein, K.J. et al. (1981) Clinical kinetics on intact cisplatin and some related species. Clin. Pharmacol. Ther., 29, 658-664.
34. Al-Dosari, M. et al. (2006) Direct assessment of promoter activity of human cytochrome p450 genes using optimized transfection in vitro and in vivo. Biosci. Rep., 26, 217-229.
35. Ogg, M.S. et al. (1997) Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. Eur. J. Drug Metab. Pharmacokinet., 22, 311-313.
36. Shangary, S. et al. (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol., 49, 223-241.